Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Drug-withdrawal.

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44350   clinical trials with a EudraCT protocol, of which   7377   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    35 result(s) found for: Drug-withdrawal.. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2015-001043-37 Sponsor Protocol Number: LORA01 Start Date*: 2015-06-30
    Sponsor Name:Erasmus MC
    Full Title: Pharmacokinetics of Lorazepam Oral Liquid in Paediatric ICU Patients
    Medical condition: Withdrawal
    Disease: Version SOC Term Classification Code Term Level
    19.0 10018065 - General disorders and administration site conditions 10013754 Drug withdrawal syndrome PT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000630-22 Sponsor Protocol Number: TV50717-CNS-30047 Start Date*: 2018-06-05
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: An Open-Label, Long-Term Safety Study Including a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period of TEV-50717 (deutetrabenazine) for the Treatment of Tourette Syndrome in Children a...
    Medical condition: Tics associated with Tourette Syndrome(TS)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) SE (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) PL (Completed) FR (Completed) NL (Ongoing) IT (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000107-36 Sponsor Protocol Number: VER-CLBP-001 Start Date*: 2021-03-24
    Sponsor Name:Vertanical GmbH
    Full Title: Proof of efficacy, maintenance of efficacy, long-term safety and investigation of the potential for dependence and abuse and the effect of abrupt drug withdrawal of VER-01 in a multicenter study in...
    Medical condition: For the treatment of patients with chronic non-specific low back pain when drug treatment is indicated and previous optimised treatments with non-opioid analgesics have not led to sufficient pain r...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-006773-92 Sponsor Protocol Number: FARM6TT8SP Start Date*: 2008-07-23
    Sponsor Name:UNIVERSITA' DEGLI STUDI DI PERUGIA
    Full Title: Sodium Valproate in the treatment of medication overuse headache: a controlled randomized clinical trial.
    Medical condition: medication overuse headache
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013753 Drug withdrawal headache LLT
    9.1 10019231 Headaches HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005971-18 Sponsor Protocol Number: 13-617 Start Date*: 2014-01-24
    Sponsor Name:University Medical Center Utrecht
    Full Title: TimeToStop (TTS) Trial, A randomised controlled trial of early versus late antiepileptic drug withdrawal after pediatric epilepsy surgery
    Medical condition: We will investigate possible cognitive benifits of early antiepileptic drug withdrawal after pediatric epilepsy surgery. The concerning medical condition is refractory epilepsy
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-003442-33 Sponsor Protocol Number: D8480C00038 Start Date*: 2005-11-22
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Randomised, Factorial, Double-blind Study to Investigate the Management of AZD2171-induced Hypertension and Efficacy of AZD2171 at Doses of 30 mg and 45 mg in Patients with Advanced Sol...
    Medical condition: Management of AZD2171-induced hypertension in patients with advanced solid tumours
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003888-22 Sponsor Protocol Number: MEF-HF-2020-01 Start Date*: 2020-11-17
    Sponsor Name:University of Zagreb School of Medicine
    Full Title: A multicENter, randomized, open-label, parallel group, pilot study to evaluate the use of sacubitril/valsartan in HeartMate 3 LVAD recipients
    Medical condition: Heart failure Heart failure with reduced ejection fraction Advanced Heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HR (Ongoing) NL (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005630-21 Sponsor Protocol Number: RG_06-180 Start Date*: 2009-04-09
    Sponsor Name:University of Birmingham [...]
    1. University of Birmingham
    2. Birmingham Heartlands Hospital
    Full Title: The effect of Pregabalin on Pain progressing in Painful Diabetic Neuropathy
    Medical condition: Diabtes and its complications, painful neuropathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000719-19 Sponsor Protocol Number: 09/100/10 Start Date*: 2011-05-05
    Sponsor Name:University of Birmingham
    Full Title: A Randomised Controlled Trial of the Efficacy and Mechanism of Levothyroxine Treatment on Pregnancy and Neonatal Outcomes in Women with Thyroid Antibodies. (TABLET: Thyroid AntiBodies and LEvoThyro...
    Medical condition: Thyroid autoimmunity and history of miscarriage or infertility.
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-002185-60 Sponsor Protocol Number: SUB9001 Start Date*: 2009-07-09
    Sponsor Name:Mundipharma Medical Company, Basel
    Full Title: RANDOMISED, CONTROLLED CLINICAL STUDY REGARDING THE FEASIBILITY OF CONVERTING OPIATE DEPENDENTS FROM METHADONE SUBSTITUTES TO SLOW RELEASE MORPHINE SULPHATE (SEVRE-LONG®)
    Medical condition: Patients with an opioid or multiple substance dependence (including opioids), actually enrolled in a methadone maintenance therapy in one of the study centres (ICD classifications F11.22, F19.22).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052970 Drug withdrawal maintenance therapy LLT
    9.1 10052730 Drug withdrawal therapies HLT
    9.1 10043413 Therapeutic procedures and supportive care NEC HLGT
    9.1 10012346 Dependence on opiates LLT
    9.1 10013663 Drug dependence LLT
    9.1 10064465 Substance-related disorders HLT
    9.1 10037176 Psychiatric disorders NEC HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002803-20 Sponsor Protocol Number: APPI2-2020-AD03 Start Date*: 2020-11-06
    Sponsor Name:Parker Instituttet
    Full Title: Colchicine treatment for patients with hand osteoarthritis: A randomised, placebo-controlled trial
    Medical condition: Hand osteoarthritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10019115 Hand osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-005102-38 Sponsor Protocol Number: 1311.4 Start Date*: 2016-04-14
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: BI 655066 / ABBV-066 (risankizumab) versus placebo In a Multicenter randomized double-blind study in patients with Moderate to severe chronic plaque psoriasis evaluating the efficacy and safety ...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-000436-28 Sponsor Protocol Number: Z102-008 Start Date*: 2011-12-07
    Sponsor Name:Zalicus, Inc.
    Full Title: A PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, RANDOMIZED WITHDRAWAL DESIGN TRIAL USING ADAPTIVE RANDOMIZATION COMPARING Z102 WITH PLACEBO IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOI...
    Medical condition: Treatment of patients with moderate to severe rheumatoid arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10039075 Rheumatoid arthritis and associated conditions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) HU (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000300-42 Sponsor Protocol Number: 03AR0298 Start Date*: 2013-01-18
    Sponsor Name:National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
    Full Title: A long-term outcome study with the IL-1 receptor antagonist Anakinra/Kineret® in patients with Neonatal onset multisystem inflammatory disease (Nomid/Cinca syndrome)
    Medical condition: neonatal onset multisystem inflammatory disease (NOMID/CINCA)
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-001045-39 Sponsor Protocol Number: CT-P43_3.1 Start Date*: 2020-11-12
    Sponsor Name:Celltrion, Inc
    Full Title: A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients with Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed)
    Trial results: View results
    EudraCT Number: 2022-002336-31 Sponsor Protocol Number: CT-P17-3.3 Start Date*: 2022-10-20
    Sponsor Name:CELLTRION, Inc
    Full Title: A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 with Humira in Patients with Moderate to Severe Chronic Plaque Psoriasis
    Medical condition: Moderate to Severe Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001147-24 Sponsor Protocol Number: ONC-2021-001 Start Date*: 2023-04-12
    Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS
    Full Title: Use of LOncastuximab Tesirine in patients with RElapsed/Refractory Diffuse Large B-Cell LYmphoma (DLBCL) or High Grade B-Cell Lymphoma (HGBCL) who have progressive disease after CAR T-cell treatmen...
    Medical condition: Patients affected by relapsed/refractory DLBCL or HGBCL failing CAR T-cell therapy
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004864 10084346 B-cell non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000952-36 Sponsor Protocol Number: CT-P39_3.1 Start Date*: 2021-02-05
    Sponsor Name:CELLTRION, Inc.
    Full Title: A Double-blind, Randomized, Active-controlled, Parallel Group, Phase 3 Study to Compare Efficacy and Safety of CT-P39 and Xolair in Patients With Chronic Spontaneous Urticaria Who Remain Symptomati...
    Medical condition: Chronic Spontaneous Urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) BG (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2020-004278-23 Sponsor Protocol Number: CT-P42_3.1 Start Date*: 2021-03-16
    Sponsor Name:CELLTRION Inc.
    Full Title: A Randomized, Active-Controlled, Double-Masked, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P42 in Comparison with Eylea in Patients with Diabetic Macular Edema
    Medical condition: Diabetic Macular Edema
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) HU (Completed) CZ (Completed) PL (Completed) LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2019-003859-11 Sponsor Protocol Number: MO41552 Start Date*: 2022-02-03
    Sponsor Name:F.Hoffmann-La Roche Ltd
    Full Title: RANDOMIZED, OPEN LABEL, MULTICENTER, PHASE III STUDY OF ENTRECTINIB VERSUS CRIZOTINIB IN PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER HARBORING ROS1 GENE REARRANGEMENTS WI...
    Medical condition: Non-small cell lung cancer with ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene rearrangements
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DE (Trial now transitioned) GR (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) SK (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) HR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 18 12:24:49 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA